Cuál es el precio por AbbVie Inc. (ABBV)

Precio por AbbVie Inc. (ABBV) es de$263.25

Cuál es la capitalización de mercado por AbbVie Inc. (ABBV)

Capitalización de mercado por AbbVie Inc. (ABBV) es $465.10B

AbbVie Inc. (ABBV) Historial de Precios

AbbVie Inc. is a global biopharmaceutical company dedicated to the discovery, development, manufacturing, and commercialization of advanced medicines. Its extensive therapeutic portfolio encompasses several key areas: Immunology and Inflammation: Leading products include HUMIRA, an injectable therapy for autoimmune and intestinal Behçet's diseases; SKYRIZI, which addresses moderate to severe plaque psoriasis in adults; and RINVOQ, a JAK inhibitor for moderate to severe active rheumatoid arthritis in adult patients. Oncology and Hematology: For blood cancers, AbbVie provides IMBRUVICA and VENCLEXTA (a BCL-2 inhibitor), both indicated for adult patients with chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL). Virology: MAVYRET offers a treatment option for individuals with chronic HCV genotype 1-6 infection. Gastroenterology and Endocrinology: The company supplies CREON, an enzyme replacement therapy for exocrine pancreatic insufficiency, and Synthroid, used to manage hypothyroidism. Linzess/Constella helps treat irritable bowel syndrome with constipation (IBS-C) and chronic idiopathic constipation. Women's Health and Urology: Lupron serves as a palliative treatment for conditions like advanced prostate cancer, endometriosis, central precocious puberty, and anemia caused by uterine fibroids. ORILISSA, a nonpeptide small molecule GnRH antagonist, is designed for women experiencing moderate to severe endometriosis pain. Neurology: AbbVie offers Duopa and Duodopa, a levodopa-carbidopa intestinal gel for Parkinson's disease, and Ubrelvy to treat migraines (with or without aura) in adults. The therapeutic formulation of Botox is also part of its offerings. Ophthalmology: Its eye care segment features Lumigan/Ganfort (a bimatoprost ophthalmic solution) and Alphagan/Combigan (an alpha-adrenergic receptor agonist), both aimed at reducing elevated intraocular pressure (IOP) in patients with open-angle glaucoma (OAG) or ocular hypertension. Restasis, a calcineurin inhibitor immunosuppressant, is provided to enhance tear production, alongside other specialized eye care products. AbbVie Inc. also engages in research collaborations, including a partnership with Dragonfly Therapeutics, Inc. The company was founded in 2012 and operates from its headquarters in North Chicago, Illinois.

Año	Rendimiento
2026 (TTM)	1.19%
2025	28.51%
2024	16.40%
2023	-7.17%
2022	27.60%
2021	21.67%
2020	19.07%
2019	0.53%
2018	-9.28%
2017	57.12%
2016	7.67%
2015	-15.03%
2014	29.37%
2013	51.26%
2012	0.00%

Año

Rendimiento

2026 (TTM)

1.19%

2025

28.51%

2024

16.40%

2023

-7.17%

2022

27.60%

2021

21.67%

2020

19.07%

2019

0.53%

2018

-9.28%

2017

57.12%

2016

7.67%

2015

-15.03%

2014

29.37%

2013

51.26%

2012

0.00%

Empresa	Precio de la acción	Cambio 1a%	País
Eli Lilly and Company LLY.US	$1.18K	55.83%	US
Johnson & Johnson JNJ.US	$268.88	54.34%	US
Roche Holding AG RO.SW	$487.71	36.25%	CH
Merck & Co., Inc. MRK.US	$152.83	90.09%	US
Novartis AG NOVN.SW	$151.26	21.91%	CH

Empresa

Precio de la acción

Cambio 1a%

País